Zimmerman BioPharmaceuticals to Propel 665 Energy

 

OKLAHOMA CITY, OK -- November 1, 2019 -- InvestorsHub NewsWire -- 665 Energy, Inc. (OTC: SSOF) has acquired Zimmerman BioPharmaceuticals, PBC (ZBP), the owner of a proprietary process that will deliver insulin to consumers at 80% of current prices. The global market for human insulin was $42.9 billion in 2017*. Within the next two years, the global demand for insulin will increase by 47%.*

The ZPB process lowers production costs, improves product cycle time, and delivers greater product stability.

 

Zimmerman BioPharmaceuticals has invested more than 7 years and $6 million in developing their proprietary process. Zimmerman's biosimilar insulin has been fully validated in pre-clinical trials and testing. The company has received an FDA recommendation to seek approval through the accelerated 505(b)(2) NDA process. 

 

Dr. Ron Zimmerman is the Founder and Chief Science Officer of Zimmerman BioPharmaceuticals, PBC. Dr. Zimmerman served as the Chief Scientist at Eli Lilly for more than 30 years. His career in the biopharma industry also includes 20 years of building and selling biopharmaceutical businesses, where he developed and patented processes that greatly improve insulin manufacturing. Dr. Zimmerman served as the co-founder and President of IPT, Inc., which sold to IVAX Corporation at a 500% internal rate of return (IRR). IVAX later sold to Teva Pharmaceutical Industries for $7.4 billion (Nasdaq: TEVA) 

 

Mr. David Wood leads Zimmerman BioPharmaceuticals as President and CEO with 35+ years experience as an operations executive in start-ups and Fortune 25 companies; delivering rapid revenue growth, and building teams to sustain growth & profitability. He was the CRO for Scient Inc., VP & GM for the $180 million Enterprise BU, and the President & COO for The Joseph Company valued at $40 million. He served as a Captain in the United States Army, and holds a Bachelor of Science, Magna Cum Laude, from Northeastern University.

 

Mr. Jim Frazier, the previous CEO of 665 Energy Inc., has tendered his resignation and controlling interest of the company effective immediately.

 

* www.psmarketresearch.com & International Diabetes Federation Global Atlas 2015

 

ABOUT Zimmerman BioPharmaceuticals, INC.

 

Zimmerman BioPharmaceuticals, Inc, is a biopharmaceutical company that owns a proprietary process that will deliver biosimilar alternatives to biologic medicines at a lower cost to consumers. Its process lowers production costs, improves product cycle time, and delivers greater product stability. Zimmerman's products have been fully validated in pre-clinical trials and testing, and has an FDA recommendation to seek approval through an accelerated process.

 

For more information, contact:

Zimmerman BioPharmaceuticals, Inc.

info@zbpinc.com

www. zbpinc.com

 

SAFE HARBOR AND INFORMATIONAL STATEMENT
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may", "would", "will", "expect", "estimate", "anticipate", "believe", "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the Company's reports filed with the SEC. The Company is not eligible to rely on the safe harbor provided by Section 21E(c) of the Exchange Act because it is not subject to filing periodic reports under Sections 13 or 15(d) of the Exchange Act.

 

 

 

Sixty Six Oilfield Servi... (CE) (USOTC:SSOF)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Sixty Six Oilfield Servi... (CE)
Sixty Six Oilfield Servi... (CE) (USOTC:SSOF)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Sixty Six Oilfield Servi... (CE)